Aim: The aim of the present study was to explore the association between CD133 expression and postoperative relapses in patients with locally advanced rectal cancer (LARC) who received neoadjuvant chemotherapy (NAC). Patients and Methods: We retrospectively examined 52 patients with LARC (cT3-4, Nany, M0) who received oxaliplatin-based NAC before surgery. CD133 expression was evaluated using immunohistochemistry and divided into low and high expression groups. Results: High CD133 expression was observed in 22 patients (42.3%). Patients with high CD133 expression had more frequent vessel invasion and relapse than those with low CD133 expression (p=0.013 and p=0.036, respectively). Comparing the low with high CD133 expression groups, the 4-year relapse-free survival rates were 82.2% vs. 46.3% (p=0.009). Multivariate analysis indicated that CD133 expression was an independent risk factor for relapse (HR=3.138; 95%CI=1.046-9.412; p=0.041). Conclusion: CD133 expression may be a predictive biomarker for postoperative relapse in patients with LARC who received NAC before surgery.

中文翻译：

---

CD133 表达可预测接受新辅助化疗的局部晚期直肠癌患者的复发

目的：本研究的目的是探讨 CD133 表达与接受新辅助化疗 (NAC) 的局部晚期直肠癌 (LARC) 患者术后复发之间的关联。患者和方法：我们回顾性检查了 52 名在手术前接受基于奥沙利铂的 NAC 的 LARC 患者（cT3-4，Nany，M0）。使用免疫组织化学评估 CD133 表达并分为低表达组和高表达组。结果：在 22 名患者 (42.3%) 中观察到高 CD133 表达。CD133 高表达的患者比 CD133 低表达的患者血管侵犯和复发的频率更高（分别为 p=0.013 和 p=0.036）。比较低 CD133 表达组与高 CD133 表达组，4 年无复发生存率为 82.2% 与 46.3% (p=0.009)。多变量分析表明，CD133 表达是复发的独立危险因素（HR=3.138；95%CI=1.046-9.412；p=0.041）。结论：CD133 表达可能是术前接受 NAC 的 LARC 患者术后复发的预测生物标志物。